全文获取类型
收费全文 | 129426篇 |
免费 | 12118篇 |
国内免费 | 5469篇 |
专业分类
耳鼻咽喉 | 2188篇 |
儿科学 | 718篇 |
妇产科学 | 2299篇 |
基础医学 | 14956篇 |
口腔科学 | 3572篇 |
临床医学 | 10545篇 |
内科学 | 13837篇 |
皮肤病学 | 2128篇 |
神经病学 | 1098篇 |
特种医学 | 6584篇 |
外国民族医学 | 124篇 |
外科学 | 19435篇 |
综合类 | 21168篇 |
现状与发展 | 27篇 |
预防医学 | 3868篇 |
眼科学 | 486篇 |
药学 | 7032篇 |
24篇 | |
中国医学 | 1715篇 |
肿瘤学 | 35209篇 |
出版年
2024年 | 173篇 |
2023年 | 1670篇 |
2022年 | 3048篇 |
2021年 | 5096篇 |
2020年 | 4500篇 |
2019年 | 4013篇 |
2018年 | 3999篇 |
2017年 | 4422篇 |
2016年 | 4968篇 |
2015年 | 5552篇 |
2014年 | 8876篇 |
2013年 | 7989篇 |
2012年 | 7898篇 |
2011年 | 8582篇 |
2010年 | 6832篇 |
2009年 | 7039篇 |
2008年 | 7264篇 |
2007年 | 7532篇 |
2006年 | 6764篇 |
2005年 | 5825篇 |
2004年 | 4728篇 |
2003年 | 4113篇 |
2002年 | 3495篇 |
2001年 | 3266篇 |
2000年 | 2809篇 |
1999年 | 2307篇 |
1998年 | 2035篇 |
1997年 | 1856篇 |
1996年 | 1571篇 |
1995年 | 1391篇 |
1994年 | 1254篇 |
1993年 | 876篇 |
1992年 | 752篇 |
1991年 | 642篇 |
1990年 | 530篇 |
1989年 | 487篇 |
1988年 | 429篇 |
1987年 | 360篇 |
1986年 | 283篇 |
1985年 | 348篇 |
1984年 | 278篇 |
1983年 | 175篇 |
1982年 | 220篇 |
1981年 | 201篇 |
1980年 | 182篇 |
1979年 | 136篇 |
1978年 | 90篇 |
1977年 | 63篇 |
1976年 | 52篇 |
1975年 | 18篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
91.
I Ahmad 《Annals of the Royal College of Surgeons of England》2015,97(7):481-486
Urothelial cell carcinoma (UCC) of the bladder is one of the most common malignancies, causing considerable morbidity and mortality worldwide. It is unique among the epithelial carcinomas as two distinct pathways to tumourigenesis appear to exist: low grade, recurring papillary tumours usually contain oncogenic mutations in FGFR3 or HRAS whereas high grade, muscle invasive tumours with metastatic potential generally have defects in the pathways controlled by the tumour suppressors p53 and retinoblastoma. Over the last two decades, a number of transgenic mouse models of UCC, containing deletions or mutations of key tumour suppressor genes or oncogenes, have helped us understand the mechanisms behind tumour development. In this summary, I present my work investigating the role of the WNT signalling cascade in UCC. 相似文献
92.
《Immunobiology》2020,225(6):152011
Anti-neutrophil antibodies are capable of activating neutrophils in sterile environments, releasing extracellular traps containing myeloperoxidase (MPO) and anti-MPO antibodies (MPO-ANCAs or anti-MPO-ANCAs), which have been implicated in the pathogenesis of several diseases. The present study evaluated systemic and tumor tissue levels of anti-MPO-ANCAs breast cancer patients, and its relation to clinicopathological characteristics. Anti-MPO-ANCAs were measured in serum and tissue samples of 150 patients by enzyme-linked immunoassay. Samples were pooled according to clinicopathological characteristics of patients. Higher anti-MPO-ANCAs levels were detected in groups presenting negative clinicopathological characteristics, such as high histological grade tumors and risk factors such as body mass index, menopausal status and early onset at diagnosis. The present data highlights anti-MPO-ANCAs as associated to poor prognosis in breast cancer, a role beyond its actually discussed role in autoimmunity and vasculitis. 相似文献
93.
目的 解析真实世界中乳腺恶性肿瘤患者的人群特征、诊断特征、中西医用药特征,为乳腺癌的临床防治提供参考。方法 采集2002年2月至2015年5月全国60家三级甲等医 院信息系统(Hospital Information System,HIS)中,出院诊断为“乳腺癌”的患者用药信息,采用SAS9.3统计软件,对人口学信息、诊断信息、医嘱用药信息等进行描述性分析。结果 39798例乳腺癌患者,平均年龄(50.93者,平均年龄)岁;多以门诊入院,入院病情以“一般”为主;合并疾病主要为高血压,骨肿瘤,联用西药以抑制肿瘤细胞增殖、治疗并发症、缓解放化疗不良反应为主;中医辨证以痰瘀互结证,气阴两虚证,肝气淤滞证,脾气亏虚证型最为常见,临床清热解毒剂、益气扶正剂,活血化瘀剂应用较多。结论 乳腺癌中西医结合治疗,联用药物广泛,临床治疗基本符合临床指南。 相似文献
94.
《Cancer cell》2021,39(11):1497-1518.e11
95.
96.
97.
98.
Bimal Bhindi Christine M. Lohse Phillip J. Schulte Ross J. Mason John C. Cheville Stephen A. Boorjian Bradley C. Leibovich R. Houston Thompson 《European urology》2019,75(5):766-772
Background
Partial nephrectomy (PN) is generally favored for cT1 tumors over radical nephrectomy (RN) when technically feasible. However, it can be unclear whether the additional risks of PN are worth the magnitude of renal function benefit.Objective
To develop preoperative tools to predict long-term estimated glomerular filtration rate (eGFR) beyond 30 d following PN and RN, separately.Design, setting, and participants
In this retrospective cohort study, patients who underwent RN or PN for a single nonmetastatic renal tumor between 1997 and 2014 at our institution were identified. Exclusion criteria were venous tumor thrombus and preoperative eGFR <15 ml/min/1.73 m2.Intervention
RN and PN.Outcome measurements and statistical analysis
Hierarchical generalized linear mixed-effect models with backward selection of candidate preoperative features were used to predict long-term eGFR following RN and PN, separately. Predictive ability was summarized using marginal , which ranges from 0 to 1, with higher values indicating increased predictive ability.Results and limitations
The analysis included 1152 patients (13 206 eGFR observations) who underwent RN and 1920 patients (18 652 eGFR observations) who underwent PN, with mean preoperative eGFRs of 66 ml/min/1.73 m2 (standard deviation [SD] = 18) and 72 ml/min/1.73 m2 (SD = 20), respectively. The model to predict eGFR after RN included age, diabetes, preoperative eGFR, preoperative proteinuria, tumor size, time from surgery, and an interaction between time from surgery and age (marginal ). The model to predict eGFR after PN included age, presence of a solitary kidney, diabetes, hypertension, preoperative eGFR, preoperative proteinuria, surgical approach, time from surgery, and interaction terms between time from surgery and age, diabetes, preoperative eGFR, and preoperative proteinuria (marginal ). Limitations include the lack of data on renal tumor complexity and the single-center design; generalizability needs to be confirmed in external cohorts.Conclusions
We developed preoperative tools to predict renal function outcomes following RN and PN. Pending validation, these tools should be helpful for patient counseling and clinical decision-making.Patient summary
We developed models to predict kidney function outcomes after partial and radical nephrectomy based on preoperative features. This should help clinicians during patient counseling and decision-making in the management of kidney tumors. 相似文献99.
100.
Lara Feulner Hamed S. Najafabadi Simon Tanguay Janusz Rak Yasser Riazalhosseini 《Urologic oncology》2019,37(2):166-175